Търсене

Nycomed on track in 2009

Nycomed on track in 2009 Strong growth of Key Products and in most emerging markets was partly offset by the negative impact of pantoprazole's patent expiry in Europe, the economic downturn and adver...

www.takeda.com/bg-bg/newsroom/news-releases/2010/nycomed-on-track-in-2009/

Nycomed and Baxter receive FDA approval for TachoSil®, an adjunct to haemostasis in cardiovascular surgery

Nycomed and Baxter receive FDA approval for TachoSil®, an adjunct to haemostasis in cardiovascular surgery For further information Media: General phone: +41 44 555 15 10Beatrix Benz, phone:...

www.takeda.com/bg-bg/newsroom/news-releases/2010/nycomed-and-baxter-receive-fda-approval-for-tachosil-an-adjunct-to-haemostasis-in-cardiovascular-surgery/

Nycomed’s novel anti-inflammatory therapy Daxas® (roflumilast) recommended for approval in the European Union for patients with COPD

Nycomed’s novel anti-inflammatory therapy Daxas® (roflumilast) recommended for approval in the European Union for patients with COPD For further information Media: General phone: +41 44 555...

www.takeda.com/bg-bg/newsroom/news-releases/2010/nycomeds-novel-anti-inflammatory-therapy-daxas-roflumilast-recommended-for-approval-in-the-european-union-for-patients-with-copd/

Jury renders positive findings on US pantoprazole (Protonix®) patent

Jury renders positive findings on US pantoprazole (Protonix®) patent For further information Media: General phone: +41 44 555 15 10Beatrix Benz, phone: +41 79 218 98 24Tobias Cottmann,...

www.takeda.com/bg-bg/newsroom/news-releases/2010/jury-renders-positive-findings-on-us-pantoprazole-protonix-patent/

Nycomed and Forest Laboratories receive complete FDA response letter for Roflumilast – no additional patient trials were requested

Nycomed and Forest Laboratories receive complete FDA response letter for Roflumilast – no additional patient trials were requested For further information Media: General phone: +41 44 555 1...

www.takeda.com/bg-bg/newsroom/news-releases/2010/nycomed-and-forest-laboratories-receive-complete-fda-response-letter-for-roflumilast--no-additional-patient-trials-were-requested/

Резултати от търсенето

Nycomed on track in 2009

Nycomed and Baxter receive FDA approval for TachoSil®, an adjunct to haemostasis in cardiovascular surgery

Nycomed’s novel anti-inflammatory therapy Daxas® (roflumilast) recommended for approval in the European Union for patients with COPD

Jury renders positive findings on US pantoprazole (Protonix®) patent

Nycomed and Forest Laboratories receive complete FDA response letter for Roflumilast – no additional patient trials were requested

2015

HCP Privacy Notice

Отвъд лекарствата

Издания на медиите

1781-1944